When will tisotumab vedotin-tftv be launched in China?

Tisotumab vedotin-tftv is the first and only ADC approved in the United States for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy.

Cervical cancer remains one of the leading causes of cancer death among women in China and globally. It is estimated that there are 110,000 new cases of cervical cancer in China every year. Treatment options are limited for patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy. Vitin-Tisotuzumab is not yet approved in China, but it could provide a new option for previously treated patients with advanced cervical cancer who currently have limited treatment options and poor efficacy. Vitin-Tisotuzumab had a manageable safety profile. In the innovaTV 204 trial, adverse events included ocular adverse events, peripheral neuropathy, and bleeding events, all of which could be managed through patient education and active monitoring in addition to timely intervention through dose adjustment and supportive care. Additionally, ocular adverse events can be managed by following required eye care and adjusting dosage as needed.

Since the original drug of Vitin-tisotumab has not yet been marketed in China, it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.